

IMPORTANT U.S. TAX INFORMATION FOR ADVANCED MEDICAL OPTICS SPIN-OFF

June 29, 2002

Dear Allergan Stockholder:

On June 29, 2002, Allergan, Inc. distributed a dividend of shares of common stock of Advanced Medical Optics, Inc. (AMO) owned by Allergan to the holders of record of Allergan common stock on June 14, 2002 (or as applicable their successors in interest). You received .2222 shares of AMO for each Allergan share owned by you (or, as applicable, your predecessor in interest) as of the record date.

No certificate or scrip representing fractional shares was issued. Instead, Mellon Investor Services, our distribution agent, aggregated all fractional shares into whole shares and sold them in the open market on behalf of Allergan stockholders who otherwise would be entitled to fractional shares. The total net proceeds of such sale will be distributed in cash on a pro rata basis to those Allergan stockholders who were otherwise entitled to receive fractional shares of AMO.

Allergan has received a ruling from the Internal Revenue Service that an Allergan stockholder's receipt of whole shares of AMO stock is tax-free for U.S. Federal income tax purposes. If you sell, or have sold, the AMO shares, you will have, or have incurred, taxable gain or loss equal to the difference between your sale proceeds and your tax basis in the AMO shares. Before you can determine your tax basis in your new AMO shares, you must first determine your tax basis in your Allergan shares, by determining (1) the date on which you acquired your Allergan shares and (2) the cost of the Allergan shares on that date. Because Allergan declared a two-for-one stock split on December 10, 1999, your tax basis in any Allergan shares acquired prior to the stock split must be divided between the shares you held prior to the stock split and the shares you held pursuant to the stock split.

Once you have determined the tax basis for your Allergan shares, you will then have to allocate that tax basis between your Allergan shares and your AMO shares. One method of valuing your Allergan shares and AMO shares for purposes of allocating tax basis would be to use the average of high and low share prices of Allergan common stock and AMO common stock on the first trading day after the spin-off, July 1, 2002. On July 1, 2002, the New York Stock Exchange reported Allergan's common stock traded as high as \$65.49 per share and as low as \$64.17 per share. The average between Allergan's high and low share price was \$64.83 per share. On July 1, 2002, the New York Stock Exchange reported AMO's common stock traded as high as \$11.00 per share and as low as \$9.90 per share. The average between AMO's high and low share price was \$10.45. **If you and your tax advisor conclude that this method is appropriate, 96.5% of your pre-distribution tax basis in Allergan shares should be allocated to your Allergan shares, and 3.5% should be allocated to your AMO shares (including any fractional interest). In order to assist you in determining your tax basis in your Allergan and AMO shares, we are providing a sample worksheet that you can complete.**

We urge you to consult your tax advisor to determine the method of allocating tax basis for your particular circumstances. The following sample calculation is based on the average of the high and low share prices of Allergan common stock and AMO common stock on the first day of trading after the spin-off, July 1, 2002:

Assume you own 100 shares of stock with a \$50 per share tax basis for a total tax basis of \$5,000, and you received 22 whole shares of AMO stock (and cash representing .22 fractional shares) as a result of the distribution. Your total tax basis in your Allergan shares would be reduced to \$4,825 (96.5% of \$5,000), or \$48.25 per share (\$4,825 divided by 100 shares). Your total tax basis in your AMO shares (including your .22 fractional share interest) would be \$175 (3.5% of \$5,000), or \$7.88 per share (\$175 divided by 22.22 shares).

The receipt of cash in lieu of fractional shares results in the recognition of gain or loss for U.S. Federal income tax purposes, measured by the difference between the cash you received for such fractional shares and your tax basis in such fractional shares (determined under the methodology described above), as described more fully in the Information Statement dated May 24, 2002 previously mailed to Allergan stockholders. You may also obtain a copy of the Information Statement at <http://www.allergan.com>.

Even if you did not dispose of any of your Allergan or AMO shares during the taxable year in which you received the AMO shares, you will still need to perform the calculation described above so that you will know what your tax basis is in your Allergan and AMO shares for the future **and** so that you can determine the amount of gain or loss required to be recognized as a result of your receipt of cash in lieu of fractional shares. For example, using the figures in the sample calculation set forth above, in which the total tax basis in AMO shares (including the .22 fractional share interest) equaled \$175 (and the per share tax basis equaled \$7.88), the tax basis of the .22 fractional share interest would be \$1.73.

You should retain this information to support the determination of your tax basis in your Allergan and AMO shares. Tax regulations require that you attach to your U.S. Federal income tax return for the year in which the AMO stock was received a statement setting forth certain prescribed information about the distribution. In order to assist you in complying with this tax requirement, we are providing a sample form of this statement to be completed by you and filed with your 2002 Federal income tax return.

The information in this letter represents our understanding of existing U.S. Federal income tax law and does not constitute tax advice. It does not purport to address all tax considerations relating to the distribution or to describe tax consequences that may apply to particular categories of stockholders, such as those who received Allergan stock through the exercise of an option or otherwise as compensation, who are not citizens or residents of the United States, or who are otherwise subject to special treatment under the Internal Revenue Code of 1986, as amended. **You are strongly urged to consult your tax advisor as to the particular tax consequences to you of the distribution, including the applicability and effect of any state, local and foreign tax laws.**